Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Tandem Diabetes Care: Hold Rating Reiterated Amidst Market Challenges and Slow Product Uptake
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $65
Tandem Diabetes Care Analyst Ratings
Goldman Sachs Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $46
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Tandem Diabetes Care (TNDM) and BioMarin Pharmaceutical (BMRN)
RBC Capital Initiates Tandem Diabetes Care(TNDM.US) With Buy Rating, Announces Target Price $65
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $57
Tandem Diabetes Care Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Stifel Nicolaus Sticks to Their Buy Rating for Tandem Diabetes Care (TNDM)
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Tandem Diabetes Care (TNDM)
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Morgan Stanley Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $45
Tandem Diabetes Care Analyst Ratings
Morgan Stanley Initiates Coverage On Tandem Diabetes Care With Equal-Weight Rating, Announces Price Target of $45
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75